Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Revenue (2024 - 2025)

Kairos Pharma's Revenue history spans 2 years, with the latest figure at $50.0 million for Q2 2025.

  • For Q2 2025, Revenue rose 416766.67% year-over-year to $50.0 million; the TTM value through Dec 2025 reached $150.0 million, up 203.43%, while the annual FY2025 figure was $50.0 million, 50.0% down from the prior year.
  • Revenue reached $50.0 million in Q2 2025 per KAPA's latest filing, roughly flat from $50.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $50.0 million in Q4 2024 to a low of -$537000.0 in Q3 2024.